Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketotifen for Oxaliplatin-Induced Neuropathy in Colorectal Cancer
NCT05624138Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy comparing Placebo Group with Ketotifen Group (2 arms). Primary endpoints: Neurotoxicity-12 item questionnaire score at 6 months, Brief Pain Inventory Short Form Worst Item Score at 6 months and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
ketotifen
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT05624138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624138.